药物涂层球囊血管成形术在终末期肾病外周动脉疾病患者中的临床结局
回顾性评估97例终末期肾病合并外周动脉疾病患者接受紫杉醇涂层球囊血管成形术的疗效与安全性,87例技术成功,随访13.4±7.4个月,12个月伤口愈合率61.5%,全因死亡率35.6%,免截肢生存率58.6%,靶病变血运重建率15.3%。伤口和环形钙化是免截肢生存的独立预测因素。
要点
- 终末期肾病患者药物涂层球囊血管成形术后12个月全因死亡率35.6%,免截肢生存率58.6%。
- 伤口存在(HR=1.404,p=0.023)和环形钙化(HR=2.076,p=0.031)是免截肢生存的独立预测因素。
- 12个月伤口愈合率61.5%,靶病变血运重建率15.3%。
核心结论
- 药物涂层球囊血管成形术在终末期肾病患者中中期有效且安全。
- 伤口和环形钙化是免截肢生存的独立预测因素。
研究设计与样本
- 回顾性评估2018年12月至2020年12月间接受药物涂层球囊血管成形术的终末期肾病合并外周动脉疾病患者97例,其中87例(63.8±10.1岁)技术成功。
主要发现
- 大多数患者Rutherford分级至少4级;平均病变长度169.8±73.8 mm,几乎所有患者有动脉钙化,31.0%有环形钙化;73.6%的靶肢体存在伤口。
- 本队列平均随访13.4±7.4个月;12个月随访时伤口愈合率61.5%,全因死亡率35.6%,免截肢生存率58.6%,13例(15.3%)患者发生靶病变血运重建。
- 随访3个月和12个月时Rutherford分级显著改善(p<0.001)。
- Cox比例风险模型显示伤口(风险比[HR]=1.404,p=0.023)和环形钙化(HR=2.076,p=0.031)是免截肢生存的独立预测因素。
临床怎么用
- 作者认为医疗专业人员可将药物涂层球囊血管成形术视为一种可行的治疗方法。
- 识别伤口存在和环形钙化作为免截肢生存的预测因素,为医疗从业者提供了更量身定制的患者管理方法,可能带来更好的结局和更精确的治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective was to determine the effectiveness and safety of paclitaxel-coated balloon angioplasty in hemodialysis patients with diabetic nephropathy (DN). MATERIALS AND METHODS: The outcomes of end-stage renal disease (ESRD) patients with peripheral artery disease (PAD) and treated with drug-coated balloon (DCB) angioplasty were retrospectively evaluated. The effectiveness outcomes were clinical improvement of the Rutherford classification and target lesion revascularization (TLR). Safety outcomes were all-cause mortality and amputation. RESULTS: Ninety-seven patients were treated with DCB angioplasty between December 2018 and December 2020. 87 (63.8±10.1 years) achieved technical success. Most patients had a Rutherford classification of at least grade 4. The mean lesion length was 169.8±73.8 mm, almost all had arterial calcification, and 31.0% had annular calcification. Wounds were present in 73.6% of the target limbs. The mean follow-up in this cohort was 13.4±7.4 months. The wound healing rate was 61.5% at the 12-month follow-up. All-cause mortality during 12 months of follow-up was 35.6%, amputation-free survival was 58.6%, and TLR was observed in 13 (15.3%) patients. At 3 and 12 months of follow-up, the Rutherford grade significantly improved (p<0.001). The Cox proportional hazards model revealed that wounds (hazard ratio [HR]=1.404, p=0.023) and annular calcification (HR=2.076, p=0.031) were independent predictors of amputation-free survival. CONCLUSIONS: Drug-coated balloon angioplasty in ESRD patients was effective and safe over the medium term. Wounds and annular calcification were independent predictors of amputation-free survival.Clinical ImpactThe effectiveness of DCB angioplasty in ESRD patients and the factors affecting major outcome prognosis in this population remain limited. This study contributes valuable insights into the effectiveness and safety of paclitaxel-coated balloon angioplasty for PAD in hemodialysis patients. Medical professionals can now regard DCB angioplasty as a viable treatment. Identifying wound presence and annular calcification as predictors of amputation-free survival equips medical practitioners with a more tailored approach to patient management, potentially resulting in enhanced outcomes and more precise treatment strategies.
引用
- Wang SX, Xiong QQ, Ren HL, et al. Clinical Outcomes of Drug-Coated Balloon Angioplasty in Peripheral Artery Disease Patients With End-Stage Renal Disease. J Endovasc Ther. 2023. PMID: 37675790. doi:10.1177/15266028231197602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。